- Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis2017 | Publication without faculty affiliation
- Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study2014 | Publication without faculty affiliation
- Syringocystadenoma papilliferum of the anogenital area and buttocks: a report of 16 cases, including human papillomavirus analysis and HRAS and BRAF V600 mutation studies2019 | Faculty of Medicine in Pilsen
- An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system2019 | First Faculty of Medicine
- Dabrafenib in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Targeted Therapies for Melanoma2020 | First Faculty of Medicine
- Long-term survival on vemurafenib monotherapy2017 | Publication without faculty affiliation
- Research Report University Hospital for clinical assessment BRF 115532Publication without faculty affiliation
- Case report of a patient with metastatic melanoma treated with several lines of systemic treatment2021 | First Faculty of Medicine
- Severe diclofenac photoallergy in a patient treated with vemurafenib2016 | Third Faculty of Medicine
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 20192020 | Third Faculty of Medicine
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 20222022 | Third Faculty of Medicine
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publication without faculty affiliation